logo-loader
viewMaxCyte Inc

MaxCyte's Doug Doerfler 'confident of providing long-term treatment' for CGD patients

Doug Doerfler, president and chief executive of MaxCyte, Inc. (LON:MXCT) tells Proactive they're to continue their collaboration with one of the world’s leading infectious disease institutes after signing a cooperative research and development agreement with the US National Institute of Allergy and Infectious Diseases (NIAD).

The two will work together to explore the development of new therapies for X-linked chronic granulomatous disease (CGD) using MaxCyte’s Flow Electroporation gene-correction platform.

Quick facts: MaxCyte Inc

Price: 107.5 GBX

AIM:MXCT
Market: AIM
Market Cap: £61.69 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read